Drug resistant cells with very large proliferative potential grow exponentially in metastatic prostate cancer
Metrics: PDF 348 views | Full Text 1155 views | ?
Krastan B. Blagoev1,2, Roumen Iordanov3, Mengxi Zhou4,5, Tito Fojo4,5 and Susan E. Bates4,5
1 National Science Foundation, Alexandria, VA 22230, USA
2 Department of Biophysics, Johns Hopkins University, Baltimore, MD 21218, USA
3 Jackson Memorial Hospital, Department of Internal Medicine, Miami, FL 33136, USA
4 Department of Medicine, Division of Hematology/Oncology, Columbia University Medical Center, New York, NY 10032, USA
5 James J. Peters Veterans Affairs Medical Center, Bronx, NY 10032, USA
|Krastan B. Blagoev,||email:||firstname.lastname@example.org|
Keywords: drug resistance; metastatic prostate cancer; exponential growth; tumor kinetics; cancer stem cells
Received: September 23, 2020 Accepted: November 12, 2020 Published: January 05, 2021
Most metastatic cancers develop drug resistance during treatment and continue to grow, driven by a subpopulation of cancer cells unresponsive to the therapy being administered. There is evidence that metastases are formed by phenotypically plastic cancer cells with stem-cell like properties. Currently the population structure and growth dynamics of the resulting metastatic tumors is unknown. Here, using scaling analysis of clinical data of tumor burden in patients with metastatic prostate cancer, we show that the drug resistant, metastasis-causing cells (MCC) are capable of producing drug resistant, exponentially growing tumors, responsible for tumor growth as a patient receives different treatments.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.